JPWO2023043658A5 - - Google Patents
Info
- Publication number
- JPWO2023043658A5 JPWO2023043658A5 JP2024540838A JP2024540838A JPWO2023043658A5 JP WO2023043658 A5 JPWO2023043658 A5 JP WO2023043658A5 JP 2024540838 A JP2024540838 A JP 2024540838A JP 2024540838 A JP2024540838 A JP 2024540838A JP WO2023043658 A5 JPWO2023043658 A5 JP WO2023043658A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- dose
- administered
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163244113P | 2021-09-14 | 2021-09-14 | |
| US63/244,113 | 2021-09-14 | ||
| US202163285435P | 2021-12-02 | 2021-12-02 | |
| US63/285,435 | 2021-12-02 | ||
| US202263400882P | 2022-08-25 | 2022-08-25 | |
| US63/400,882 | 2022-08-25 | ||
| PCT/US2022/042944 WO2023043658A2 (en) | 2021-09-14 | 2022-09-08 | Method of treating multiple myeloma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024535132A JP2024535132A (ja) | 2024-09-26 |
| JPWO2023043658A5 true JPWO2023043658A5 (https=) | 2025-08-25 |
| JP2024535132A5 JP2024535132A5 (https=) | 2025-08-25 |
Family
ID=85603424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540838A Pending JP2024535132A (ja) | 2021-09-14 | 2022-09-08 | 多発性骨髄腫を治療する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240392028A1 (https=) |
| EP (1) | EP4401839A4 (https=) |
| JP (1) | JP2024535132A (https=) |
| KR (1) | KR20240055101A (https=) |
| AU (1) | AU2022346750A1 (https=) |
| CA (1) | CA3231073A1 (https=) |
| MX (1) | MX2024003215A (https=) |
| WO (1) | WO2023043658A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025194030A1 (en) * | 2024-03-15 | 2025-09-18 | Alexion Pharmaceuticals, Inc. | Treatment of mayo stage iiib light chain amyloidosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5553963B2 (ja) * | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
| CR20190291A (es) * | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
| US20190298827A1 (en) * | 2018-04-03 | 2019-10-03 | Janssen Biotech, Inc. | Methods of Treating Multiple Myeloma |
| EP4058479A4 (en) * | 2019-11-15 | 2024-02-28 | University of Tennessee Research Foundation | MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS |
| AU2021339851A1 (en) * | 2020-09-14 | 2023-04-13 | Caelum Biosciences, Inc. | Method of treating amyloidosis |
-
2022
- 2022-09-08 AU AU2022346750A patent/AU2022346750A1/en active Pending
- 2022-09-08 CA CA3231073A patent/CA3231073A1/en active Pending
- 2022-09-08 KR KR1020247011913A patent/KR20240055101A/ko active Pending
- 2022-09-08 EP EP22870530.7A patent/EP4401839A4/en active Pending
- 2022-09-08 MX MX2024003215A patent/MX2024003215A/es unknown
- 2022-09-08 US US18/691,365 patent/US20240392028A1/en active Pending
- 2022-09-08 WO PCT/US2022/042944 patent/WO2023043658A2/en not_active Ceased
- 2022-09-08 JP JP2024540838A patent/JP2024535132A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| CN104684552B (zh) | 组合及其用途 | |
| RU2014105496A (ru) | Способы снижения числа эозинофилов | |
| CN1281468A (zh) | 用抗ErbB2抗体治疗 | |
| MXPA02002037A (es) | Dosificaciones para el tratamiento con anticuerpos anti-erb2. | |
| JP2021514003A5 (https=) | ||
| RU2007102055A (ru) | Оптимизированное введение доз анти-cd4-антител для индукции толерантности у приматов | |
| CN119424632A (zh) | 治疗结直肠癌的联用药物组合物 | |
| JPWO2023043658A5 (https=) | ||
| JPWO2021097220A5 (https=) | ||
| JPWO2022098955A5 (https=) | ||
| JP2013542188A (ja) | 治療用第ｖｉｉｉ因子抗体 | |
| TW202508630A (zh) | 治療表現ｃｄ２０之ｂ細胞癌症之方法 | |
| KR20210131316A (ko) | Sumo-활성화 효소 저해제 및 관문 저해제의 투여 | |
| JPWO2022056484A5 (https=) | ||
| KR20240133743A (ko) | Al 아밀로이드증 치료 방법 | |
| TW202144007A (zh) | 一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途 | |
| US20240360215A1 (en) | Anti-cd19 antibody in the treatment of cns lymphoma | |
| CN119031933B (zh) | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 | |
| JP7217287B2 (ja) | アミロイド症の処置および予防 | |
| RU2025114695A (ru) | Антитело к c5, слитое с фактором h, для лечения комплементопосредованных заболеваний | |
| JPWO2019215701A5 (https=) | ||
| JPWO2023003815A5 (https=) | ||
| CN117815387A (zh) | Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物 |